These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 15505811)
1. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4. Park H; Yeom MS; Lee S Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811 [TBL] [Abstract][Full Text] [Related]
2. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305 [TBL] [Abstract][Full Text] [Related]
3. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247 [TBL] [Abstract][Full Text] [Related]
4. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031 [TBL] [Abstract][Full Text] [Related]
5. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A. Kim DM; Yang K; Yang BS Exp Mol Med; 2003 Oct; 35(5):421-30. PubMed ID: 14646596 [TBL] [Abstract][Full Text] [Related]
6. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes. Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914 [TBL] [Abstract][Full Text] [Related]
7. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations. Villacañas O; Pérez JJ; Rubio-Martínez J J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373 [TBL] [Abstract][Full Text] [Related]
8. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity. Calbó J; Serna C; Garriga J; Graña X; Mazo A Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028 [TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460 [TBL] [Abstract][Full Text] [Related]
10. Novel Cdk inhibitors restore TGF-beta sensitivity in cdk4 overexpressing epithelial cells. Soni R; Fretz H; Muller L; Schoepfer J; Chaudhuri B Biochem Biophys Res Commun; 2000 Jun; 272(3):794-800. PubMed ID: 10860833 [TBL] [Abstract][Full Text] [Related]
11. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. Van Dross R; Yao S; Asad S; Westlake G; Mays DJ; Barquero L; Duell S; Pietenpol JA; Browning PJ J Natl Cancer Inst; 2005 May; 97(9):656-66. PubMed ID: 15870436 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Fåhraeus R; Laín S; Ball KL; Lane DP Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345 [TBL] [Abstract][Full Text] [Related]
14. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex. Nakanishi M; Kagawa Y; Takahashi H; Matsushime H Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388 [TBL] [Abstract][Full Text] [Related]
15. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells. Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity. Coppock DL; Buffolino P; Kopman C; Nathanson L Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260 [TBL] [Abstract][Full Text] [Related]
17. Solution structure of p21(Waf1/Cip1/Sdi1) C-terminal domain bound to Cdk4. Sung YH; Shin J; Shin J; Lee W J Biomol Struct Dyn; 2001 Dec; 19(3):419-27. PubMed ID: 11790141 [TBL] [Abstract][Full Text] [Related]
18. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors. Sims PA; Wong CF; McCammon JA J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762 [TBL] [Abstract][Full Text] [Related]
19. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Tsihlias J; Zhang W; Bhattacharya N; Flanagan M; Klotz L; Slingerland J Oncogene; 2000 Feb; 19(5):670-9. PubMed ID: 10698512 [TBL] [Abstract][Full Text] [Related]
20. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Sweeney KJ; Sarcevic B; Sutherland RL; Musgrove EA Oncogene; 1997 Mar; 14(11):1329-40. PubMed ID: 9178893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]